Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Grainne d'Ancona

Principal Pharmacist at Guy's and St Thomas' NHS Foundation Trust

Recent stories

  • Illustration of chronic obstructive pulmonary disease (COPD)

    Chronic obstructive pulmonary disease: clinical phenotypes and implications for managementSubscription

    10 JUN 2016

    Phenotyping patients with chronic obsructive pulmonary disease allows their separation into distinct categories that differentiate their prognosis and response to treatment, producing clinically meaningful outcomes.

  • Inhaled corticosteroids (ICSs) are indicated in the management of most patients with asthma and some patients with chronic obstructive pulmonary disease (COPD). In the image, a scanning electron micrograph (SEM) showing alveoli and pulmonary blood vessels

    Inhaled corticosteroids: managing side effectsSubscription

    18 FEB 2015Comments (3)

    Inhaled corticosteroids are commonly prescribed but need careful management to minimise the risk of side effects.

  • Generic prescribing is not appropriate for inhaled drugsSubscription

    8 JAN 2015Comments (3)

    The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing. One product is DuoRespSpiromax, a cheaper “branded generic” of Symbicort Turbohaler, both containing

  • Primum non nocereSubscription

    PJ, 7 June 2014, Vol 292, No 7813

  • Our concerns with Relvar ElliptaSubscription

    PJ, 22 February 2014, Vol 292, No 7798

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.